Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XFUX | ISIN: IL0011313900 | Ticker-Symbol: GPH
Frankfurt
28.03.24
08:00 Uhr
0,290 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GALMED PHARMACEUTICALS LTD Chart 1 Jahr
5-Tage-Chart
GALMED PHARMACEUTICALS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,3060,32216:23
0,3060,32215:23
PR Newswire
361 Leser
Artikel bewerten:
(2)

Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

TEL AVIV, Israel, June 1, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments

Recent Developments

  • Initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC), a rare disease for which there is no approved treatment;
  • Phase 2 proof of concept PSC study to be conducted in collaboration with the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University ;
  • Formed a strategic partnership with Onkai, Inc., leading an investment round of $6 million in Onkai, an AI-powered digital platform that facilitates health equity in underserved communities across the US, Enabling faster and diverse enrollment to clinical trials;
  • The Company is discontinuing its evaluation of strategic alternatives; and
  • Nasdaq notified the Company that it regained compliance with the Nasdaq minimum bid price rule.

Financial Summary - First Quarter 2023 vs. First Quarter 2022:

  • Cash and cash equivalents, short term deposit, restricted cash and marketable debt securities totaled $12.2 million as of March 31, 2023, compared to $13.8 million at December 31, 2022 .
  • Net loss amounted to $1.8 million, or $1.09 per share, for the three months ended March 31, 2023, compared to a net loss of $6.1 million, or $3.67 per share, for the three months ended March 31, 2022 .
  • Research and development expenses amounted to approximately $1.1 million for the three months ended March 31, 2023, compared to approximately $4.8 million for the three months ended March 31, 2022 . The decrease resulted primarily from a decrease in clinical trial expenses.
  • General and administrative expenses amounted to approximately $0.9 million for the three months ended March 31, 2023, compared to approximately $1.3 million for the three months ended March 31, 2022 . The decrease resulted primarily from a decrease in share based compensation and professional services expenses.
  • Financial income, net amounted to approximately $0.2 million for the three months ended March 31, 2023, compared to financial expense of $0.05 million for the three months ended March 31, 2022 .

About Galmed Pharmaceuticals Ltd.

We are a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. We have focused almost exclusively on developing Aramchol for the treatment of NASH and are currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.

Forward-Looking Statements:

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause Galmed's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the timing and cost of Galmed's planned PSC clinical trial and our pivotal Phase 3 ARMOR trial, or the ARMOR Study (if re-initated) or any other pre-clinical or clinical trials; completion and receiving favorable results of our planned PSC clinical trial and our the ARMOR Study for Aramchol (if re-initiated) or any other pre-clinical or clinical trial; the impact of the COVID-19 pandemic; regulatory action with respect to Aramchol or any other product candidate by the FDA or the EMA; the commercial launch and future sales of Aramchol or any other future products or product candidates; Galmed's ability to comply with all applicable post-market regulatory requirements for Aramchol or any other product candidate in the countries in which it seeks to market the product; Galmed's ability to achieve favorable pricing for Aramchol or any other product candidate; Galmed's expectations regarding the commercial market for NASH patients or any other indication; third-party payor reimbursement for Aramchol or any other product candidate; Galmed's estimates regarding anticipated capital requirements and Galmed's needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; the development and approval of the use of Aramchol or any other product candidate for additional indications or in combination therapy; and Galmed's expectations regarding licensing, acquisitions and strategic operations/. More detailed information about the risks and uncertainties affecting Galmed is contained under the heading "Risk Factors" included in Galmed's most recent Annual Report on Form 20-F filed with the SEC on March 29, 2023, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

GALMED PHARMACEUTICALS LTD.


Consolidated Balance Sheets


U.S. Dollars in thousands, except share data and per share data













As of



As of





March 31,



December 31,





2023



2022





Unaudited



Audited


Assets




















Current assets










Cash and cash equivalents


$

1,672


$

2,016


Short term deposit



754



-


Restricted Cash



114



114


Marketable debt securities



9,726



11,769


Other receivables



568



825


Total current assets



12,834



14,724












Right of use assets



176



223


Property and equipment, net



105



114


Investment in convertible loan



1,676



1,500


Total non-current assets


1,957



1,837












Total assets


$

14,791


$

16,561












Liabilities and stockholders' equity




















Current liabilities










Trade payables

$

2,266


$

2,560


Other payables



535



534


Total current liabilities



2,801



3,094












Non-current liabilities










Lease obligation


$

-


$

44


Total non-current liabilities



-



44












Ordinary shares par value NIS 0.01 per share; Authorized 20,000,000; Issued and










outstanding: 1,680,232 shares as of March 31, 2023 and December 31, 2022 *)



70



70


Additional paid-in capital



200,435



200,138


Accumulated other comprehensive loss



(645)



(745)


Accumulated deficit



(187,870)



(186,040)


Total stockholders' equity



11,990



13,423












Total liabilities and stockholders' equity


$

14,791


$

16,561


The accompanying notes are an integral part of the interim consolidated financial statements.

*) Retroactively adjusted to reflect the reverse split





















GALMED PHARMACEUTICALS LTD.


Consolidated Statements of Operations (Unaudited)


U.S. Dollars in thousands, except share data and per share data













Three months ended







March 31,






2023


2022



Research and development expenses


$

1,083


$

4,796














General and administrative expenses



919



1,296














Total operating expenses



2,002



6,092














Financial (income) expense, net



(172)



51














Net loss


$

1,830


$

6,143














Basic and diluted net loss per share


$

1.09


$

3.67



Weighted-average number of shares outstanding used in
computing basic and diluted net loss *)





















per share



1,680,232



1,672,566














*) Retroactively adjusted to reflect the reverse split



GALMED PHARMACEUTICALS LTD.


Consolidated Statements of Cash Flows (Unaudited)


U.S. Dollars in thousands










Three months ended




March 31,




2023


2022


Cash flow from operating activities


















Net loss

$

(1,830)


$

(6,143)











Adjustments required to reconcile net loss to net cash used in operating activities









Depreciation and amortization



8



9


Stock-based compensation expense



297



457


Amortization of premium on marketable debt securities



10



31


Amortization of discount on long term assets



(176)



-


Interest income from short-term deposits



(4)



-


Loss from realization of marketable debt securities



32



145


Finance expenses



4



(10)


Changes in operating assets and liabilities:









Decrease in other accounts receivable



257



282


Decrease in trade payables



(294)



(36)


Increase (decrease) in other accounts payable



1



(187)


Net cash used in operating activities



(1,695)



(5,452)











Cash flow from investing activities









Purchase of available for sale securities



2,494



-


Investment in short term deposits



(750)



-


Consideration from sale of available for sale securities



(393)



6,309


Net cash provided by investing activities



1,351



6,309











Increase (decrease) in cash and cash equivalents and restricted cash



(344)



857


Cash and cash equivalents and restricted cash at the beginning of the period



2,130



2,998


Cash and cash equivalents and restricted cash at the end of the period


$

1,786


$

3,855











Supplemental disclosure of cash flow information:









Cash received from interest

$

64

$

77











Logo - https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg

SOURCE Galmed Pharmaceuticals Ltd.

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2023 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.